AGLHIGH SIGNALRISK10-K

AGL received NYSE delisting notice for trading below $1.00 per share and is pursuing a reverse stock split to regain compliance.

The NYSE delisting notice represents a significant reputational and liquidity risk that could further pressure the stock price and limit institutional investor participation. The company's plan for a reverse stock split scheduled for shareholder approval in March 2026 indicates management is taking immediate action, but this typically signals underlying fundamental distress rather than addressing root operational issues.

Comparing 2026-02-25 vs 2025-02-25View on EDGAR →
FINANCIAL ANALYSIS

AGL's financial position deteriorated meaningfully across all key metrics, with operating losses substantially widening and operating cash flow burn nearly doubling year-over-year. The company's balance sheet contracted significantly, with total assets declining 26.7% to $1.3B and stockholders' equity falling 28.8% to $471.0M. The combination of widening losses, increased cash burn, and shrinking asset base suggests mounting financial pressure that aligns with the stock's poor performance triggering the NYSE compliance issue.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
-83.1%
-$57.8M→-$105.8M

Operating cash flow fell 83.1% — earnings quality concerns; investigate working capital changes and non-cash items.

Operating Income
P&L
-58.6%
-$292.1M→-$463.2M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Net Income
P&L
-50.4%
-$260.2M→-$391.3M

Net income declined 50.4% — review whether driven by operations, interest costs, or non-recurring items.

Interest Expense
P&L
+47.1%
$4.5M→$6.7M

Interest expense surged 47.1% — significant debt increase or rising rates materially impacting earnings.

Stockholders Equity
Balance Sheet
-28.8%
$661.8M→$471.0M

Equity decreased 28.8% — buybacks or losses reducing book value, monitor solvency ratios.

Total Assets
Balance Sheet
-26.7%
$1.7B→$1.3B

Total assets contracted 26.7% — asset sales, write-downs, or balance sheet optimization underway.

Current Assets
Balance Sheet
-24.8%
$1.5B→$1.1B

Current assets declined 24.8% — monitor working capital adequacy and short-term liquidity.

LANGUAGE CHANGES
NEW — 2026-02-25
PRIOR — 2025-02-25
ADDED
As of February 19, 2026, there were 414,869,759 shares of common stock outstanding.
They appear in several places throughout this Report and include, without limitation, statements regarding our intentions, beliefs, assumptions or current expectations concerning, among other things, our financial position, results of operations, cash flows, prospects, growth strategies, and the impact of the new CMS LEAD Model (each as defined below).
On November 5, 2025, we received written notice (the Notice ) from the NYSE informing us that we are no longer in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of our common stock was less than $1.00 per share over a consecutive 30 trading-day period ended November 4, 2025 (the Price Criteria for Capital or Common Stock ).
We can regain compliance at any time within the six-month period following receipt of the Notice if, on the last trading day of any calendar month during the cure period (or the last trading day of the cure period), we have a closing share price of at least $1.00 and an average closing share price of at least $1.00 over the prior 30 trading-day period ending on the last trading day of the applicable calendar month or the cure period.
To regain compliance with the Price Criteria for Capital or Common Stock, we are pursuing a reverse stock split, subject to approval by our stockholders.
+7 more — sign up free →
REMOVED
As of February 21, 2025, there were 412,303,066 shares of common stock outstanding.
They appear in several places throughout this Report and include, without limitation, statements regarding our intentions, beliefs, assumptions or current expectations concerning, among other things, our financial position, results of operations, cash flows, prospects, and growth strategies.
Our platform has enabled us to grow our total membership by 36% and revenue by 40% from December 31, 2023 to December 31, 2024.
Our purpose-built platform is comprised of an integrated set of capabilities designed to continuously improve, helping our anchor physician groups to identify gaps in care, integrate seamlessly with payors, sustain their practices, and identify untapped opportunities for improved outcomes.
The premium payments to payors are based on county-level benchmark rates established by CMS and payors annual bid of amounts necessary to cover the cost of a standard MA patient, and are influenced by several factors, including, but not limited to, the applicable MA plan s STAR rating and CMS risk-adjustment model, which compensates payors based on the health status (acuity) of each individual patient in the preceding calendar year.
+7 more — sign up free →
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →